| Chan, David |
| Recruiting | 3 | 690 | RoW | Atorvastatin 20mg, Placebos | Chinese University of Hong Kong | Chronic Subdural Hematoma | 09/22 | 03/23 | | |
| Completed | 3 | 300 | Europe, Canada, US, RoW | 89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX) | Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd | Clear Cell Renal Cell Carcinoma | 10/22 | 11/22 | | |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects |
|
|
| Recruiting | 3 | 750 | Europe, US | Placebo, GLSI-100 | Greenwich LifeSciences, Inc. | Breast Cancer | 12/26 | 12/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT04438304: A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) |
|
|
| Active, not recruiting | 2 | 63 | RoW | 64Cu-SARTATE, 64Cu-MeCOSar-Octreotate | Clarity Pharmaceuticals Ltd | Neuroendocrine Tumors | 10/24 | 10/24 | | |
NCT04798781: Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 16 | US | Telatinib, Keytruda, pembrolizumab | Andrew Hendifar, MD, EOC Pharma | Gastric Cancer, Hepatocellular Carcinoma | 02/24 | 02/25 | | |
NCT06445114: Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer |
|
|
| Not yet recruiting | 2 | 50 | US | Cisplatin, Chemoradiation | Zachary Zumsteg | Oropharyngeal Cancer, Carcinoma | 03/32 | 03/32 | | |
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer |
|
|
| Recruiting | 2 | 88 | US | Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516 | Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd. | Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer | 09/25 | 09/25 | | |
|
NCT06123286: Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms |
|
|
| Not yet recruiting | 1 | 30 | US | Tart Cherry, Omega 3 FA (Fish Oil) | Philip Chang, The Cherry Marketing Institute | Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain | 01/27 | 01/27 | | |
| Recruiting | N/A | 600 | Canada | Implementation of WAPPS-Hemo personalized dosing regimen | McMaster University | Hemophilia A, Hemophilia B | 09/22 | 09/23 | | |
NCT05143216: High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study |
|
|
| Recruiting | N/A | 23 | RoW | Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula), High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask) | Dr. David Yuen Chung CHAN | Chronic Subdural Hematoma | 12/22 | 12/23 | | |
HOPE, NCT04725851: High Concentration Oxygen for Pneumocephalus After Evacuation of Chronic Subdural Haematoma |
|
|
| Recruiting | N/A | 36 | RoW | High concentration Oxygen therapy, Control: Room Air or Low concentration Oxygen | Chinese University of Hong Kong | Chronic Subdural Hematoma, Recurrence, Oxycephaly | 12/23 | 12/24 | | |
NCT04403802: Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy |
|
|
| Completed | N/A | 28 | US | Voxx Human Performance Technology Socks, Placebo Socks | Arash Asher, MD, VoxxLife | Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy, Neuropathy | 05/24 | 05/24 | | |
ACTRN12618001819213: A novel PET (positron emission tomography) tracer for donut-like PET findings in patients with neuroendocrine tumours |
|
|
| Recruiting | N/A | 10 | | | Northern Sydney Local Health District, Sydney Vital | Neuroendocrine tumours | | | | |
| Hool, Hugo |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04798781: Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 16 | US | Telatinib, Keytruda, pembrolizumab | Andrew Hendifar, MD, EOC Pharma | Gastric Cancer, Hepatocellular Carcinoma | 02/24 | 02/25 | | |
NCT06445114: Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer |
|
|
| Not yet recruiting | 2 | 50 | US | Cisplatin, Chemoradiation | Zachary Zumsteg | Oropharyngeal Cancer, Carcinoma | 03/32 | 03/32 | | |
| Terminated | 1 | 32 | US | UCT-01-097, Gemcitabine, Gemzar, Paclitaxel, Abraxane | 1200 Pharma, LLC | Advanced Solid Tumor | 02/24 | 02/24 | | |
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer |
|
|
| Active, not recruiting | 1 | 70 | US, RoW | TORL-2-307-MAB | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/25 | | |
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer |
|
|
| Recruiting | 1 | 70 | US, RoW | TORL-2-307-ADC | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 01/26 | | |
NCT06123286: Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms |
|
|
| Not yet recruiting | 1 | 30 | US | Tart Cherry, Omega 3 FA (Fish Oil) | Philip Chang, The Cherry Marketing Institute | Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain | 01/27 | 01/27 | | |
NCT04403802: Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy |
|
|
| Completed | N/A | 28 | US | Voxx Human Performance Technology Socks, Placebo Socks | Arash Asher, MD, VoxxLife | Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy, Neuropathy | 05/24 | 05/24 | | |
MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer |
|
|
| Recruiting | N/A | 750 | Canada, US | MRD | Exact Sciences Corporation, NSABP Foundation Inc | Colorectal Cancer | 02/28 | 02/28 | | |
